ArticleCancer research2015
Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis.
Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection.Journal of gastrointestinal oncology · 2026Article
- High level dynein impairs mitochondrial distribution and differentiation of rhabdomyosarcoma cells.iScience · 2026Article
- Genomic mapping reveals cisplatin disruption of protein phosphorylation signalling genome-wide.Metallomics : integrated biometal science · 2026Article
- What is known and unknown about the role of neuroendocrine genesFrontiers in endocrinology · 2025Review
- Pain - related methylation driver genes affect the prognosis of pancreatic cancer patients by altering immune function and perineural infiltration.Frontiers in genetics · 2025Article
- Epigenetic regulation of individual components of combined hepatocellular-cholangiocarcinoma.PloS one · 2025Article
- The landscape of somatic mutations in lymphoblastoid cell lines.Cell genomics · 2023Article
- Review
- Identification of molecular subtypes and a six-gene risk model related to cuproptosis for triple negative breast cancer.Frontiers in genetics · 2022Article
- Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways.PloS one · 2021Article
- Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.Molecular genetics and genomics : MGG · 2020Article
- Haplotype Block Analysis Reveals Candidate Genes and QTLs for Meat Quality and Disease Resistance in Chinese Jiangquhai Pig Breed.Frontiers in genetics · 2020Article
- DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma.Clinical epigenetics · 2019Article
- BioMethyl: an R package for biological interpretation of DNA methylation data.Bioinformatics (Oxford, England) · 2019Article
- Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.Cellular and molecular life sciences : CMLS · 2019Review
- Simultaneous Interrogation of Cancer Omics to Identify Subtypes With Significant Clinical Differences.Frontiers in genetics · 2019Article
- The impact of phosphatases on proliferative and survival signaling in cancer.Cellular and molecular life sciences : CMLS · 2018Review
- Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer.Oncotarget · 2018Article
- Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.Journal of the National Cancer Institute · 2017Article
- BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.Oncogenesis · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
The protein tyrosine phosphatase receptor PTPRN2 is expressed predominantly in endocrine and neuronal cells, where it functions in exocytosis. We found that its immature isoform proPTPRN2 is overexpressed in various cancers, including breast cancer. High proPTPRN2 expression was associated strongly with lymph node-positive breast cancer and poor clinical outcome. Loss of proPTPRN2 in breast cancer cells promoted apoptosis and blocked tumor formation in mice, whereas enforced expression of proPTPRN2 in nontransformed human mammary epithelial cells exerted a converse effect. Mechanistic investigations suggested that ProPTPRN2 elicited these effects through direct interaction with TRAF2, a hub scaffold protein for multiple kinase cascades, including ones that activate NF-κB. Overall, our results suggest PTPRN2 as a novel candidate biomarker and therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.